{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:20:14Z","timestamp":1762809614505},"reference-count":43,"publisher":"Journal of Biomedical Research","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2024]]},"DOI":"10.7555\/jbr.37.20230284","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T02:36:18Z","timestamp":1717122978000},"page":"464","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment"],"prefix":"10.7555","volume":"38","author":[{"given":"Yifan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongbin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Devarbhavi H, Asrani SK, Arab JP, et al.  Global burden of liver disease: 2023 update[J]. <i>J Hepatol<\/i>, 2023, 79(2): 516\u2013537.","DOI":"10.1016\/j.jhep.2023.03.017"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.2","doi-asserted-by":"publisher","unstructured":"Lingala S, Ghany MG.  Natural history of hepatitis C[J]. <i>Gastroenterol Clin North Am<\/i>, 2015, 44(4): 717\u2013734.","DOI":"10.1016\/j.gtc.2015.07.003"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.3","doi-asserted-by":"publisher","unstructured":"Martinello M, Solomon SS, Terrault NA, et al.  Hepatitis C[J]. <i>Lancet<\/i>, 2023, 402(10407): 1085\u20131096.","DOI":"10.1016\/S0140-6736(23)01320-X"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Zhu X, Wang M, Liu M, et al.  Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection[J]. <i>Per Med<\/i>, 2019, 16(5): 421\u2013429.","DOI":"10.2217\/pme-2018-0121"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.5","doi-asserted-by":"publisher","unstructured":"Marascio N, Quirino A, Barreca GS, et al.  Discussion on critical points for a tailored therapy to cure hepatitis C virus infection[J]. <i>Clin Mol Hepatol<\/i>, 2019, 25(1): 30\u201336.","DOI":"10.3350\/cmh.2018.0061"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.6","doi-asserted-by":"publisher","unstructured":"Naggie S, Cooper C, Saag M, et al.  Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1[J]. <i>N Engl J Med<\/i>, 2015, 373(8): 705\u2013713.","DOI":"10.1056\/NEJMoa1501315"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.7","doi-asserted-by":"publisher","unstructured":"Scaglione V, Mazzitelli M, Costa C, et al.  Virological and clinical outcome of DAA containing regimens in a cohort of patients in Calabria Region (Southern Italy)[J]. <i>Medicina (Kaunas)<\/i>, 2020, 56(3): 101.","DOI":"10.3390\/medicina56030101"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.8","doi-asserted-by":"publisher","unstructured":"Carrat F, Fontaine H, Dorival C, et al.  Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study[J]. <i>Lancet<\/i>, 2019, 393(10179): 1453\u20131464.","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.9","doi-asserted-by":"publisher","unstructured":"Itakura J, Kurosaki M, Setoyama H, et al.  Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis[J]. <i>J Gastroenterol<\/i>, 2021, 56(5): 470\u2013478.","DOI":"10.1007\/s00535-021-01782-3"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.10","doi-asserted-by":"publisher","unstructured":"Yen YH, Kuo FY, Kee KM, et al.  APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level[J]. <i>PLoS One<\/i>, 2018, 13(6): e0199760.","DOI":"10.1371\/journal.pone.0199760"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.11","doi-asserted-by":"publisher","unstructured":"Cholankeril G, Kramer JR, Chu J, et al.  Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease[J]. <i>J Hepatol<\/i>, 2023, 78(3): 493\u2013500.","DOI":"10.1016\/j.jhep.2022.10.035"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.12","doi-asserted-by":"publisher","unstructured":"Tamaki N, Kurosaki M, Tanaka K, et al.  Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C[J]. <i>J Viral Hepat<\/i>, 2013, 20(1): 72\u201376.","DOI":"10.1111\/j.1365-2893.2012.01635.x"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.13","doi-asserted-by":"publisher","unstructured":"Monto A.  Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol[J]. <i>Hepatology<\/i>, 2002, 36(3): 729\u2013736.","DOI":"10.1053\/jhep.2002.35064"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.14","doi-asserted-by":"publisher","unstructured":"Hui JM, Sud A, Farrell GC, et al.  Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression[J]. <i>Gastroenterology<\/i>, 2003, 125(6): 1695\u20131704.","DOI":"10.1053\/j.gastro.2003.08.032"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.15","doi-asserted-by":"publisher","unstructured":"Afsari A, Lee E, Shokrani B, et al.  Clinical and pathological risk factors associated with liver fibrosis and steatosis in African-Americans with chronic hepatitis C[J]. <i>Dig Dis Sci<\/i>, 2017, 62(8): 2159\u20132165.","DOI":"10.1007\/s10620-017-4626-7"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.16","doi-asserted-by":"publisher","unstructured":"Sterling RK, Lissen E, Clumeck N, et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection[J]. <i>Hepatology<\/i>, 2006, 43(6): 1317\u20131325.","DOI":"10.1002\/hep.21178"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.17","doi-asserted-by":"publisher","unstructured":"Pawlotsky JM, Negro F, Aghemo A, et al.  EASL recommendations on treatment of hepatitis C: final update of the series[J]. <i>J Hepatol<\/i>, 2020, 73(5): 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.18","doi-asserted-by":"publisher","unstructured":"Hagstr\u00f6m H, Talb\u00e4ck M, Andreasson A, et al.  Repeated FIB-4 measurements may help identify individuals at risk of severe liver disease[J]. <i>J Hepatol<\/i>, 2020, 73(5): 1023\u20131029.","DOI":"10.1016\/j.jhep.2020.06.007"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.19","doi-asserted-by":"publisher","unstructured":"Trifan A, Stanciu C.  Checkmate to liver biopsy in chronic hepatitis C?[J]. <i>World J Gastroenterol<\/i>, 2012, 18(39): 5514\u20135520.","DOI":"10.3748\/wjg.v18.i39.5514"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.20","doi-asserted-by":"publisher","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al.  Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases[J]. <i>Hepatology<\/i>, 2018, 68(2): 723\u2013750.","DOI":"10.1002\/hep.29913"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.21","doi-asserted-by":"publisher","unstructured":"El-Sherif O, Jiang ZG, Tapper EB, et al.  Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection[J]. <i>Gastroenterology<\/i>, 2018, 154(8): 2111\u20132121.e8.","DOI":"10.1053\/j.gastro.2018.03.022"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.22","unstructured":"R Core Team. The R project for statistical computing[EB\/OL]. [2023-10-01]. <a href=\"https:\/\/www.R-project.org\/\">https:\/\/www.R-project.org\/<\/a>."},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.23","doi-asserted-by":"publisher","unstructured":"Hu SX, Kyulo NL, Xia VW, et al.  Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients[J]. <i>J Clin Gastroenterol<\/i>, 2009, 43(8): 758\u2013764.","DOI":"10.1097\/MCG.0b013e31818be17c"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.24","doi-asserted-by":"publisher","unstructured":"Nahon P, Bourcier V, Layese R, et al.  Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications[J]. <i>Gastroenterology<\/i>, 2017, 152(1): 142\u2013156.e2.","DOI":"10.1053\/j.gastro.2016.09.009"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.25","doi-asserted-by":"publisher","unstructured":"Feng L, Sun K, Zhang J, et al.  A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort study[J]. <i>BMJ Open<\/i>, 2015, 5(9): e008032.","DOI":"10.1136\/bmjopen-2015-008032"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.26","doi-asserted-by":"publisher","unstructured":"Ferra-Murcia S, Collado-Romacho AR, Nievas-Soriano BJ, et al.  Real-life early anthropometric, lipid and liver changes after direct-acting antiviral therapy in PLWHIV with HCV co-infection[J]. <i>J Clin Med<\/i>, 2022, 11(9): 2639.","DOI":"10.3390\/jcm11092639"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.27","doi-asserted-by":"publisher","unstructured":"Serfaty L, Andreani T, Giral P, et al.  Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C[J]. <i>J Hepatol<\/i>, 2001, 34(3): 428\u2013434.","DOI":"10.1016\/S0168-8278(00)00036-2"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.28","unstructured":"Wawrzynowicz-Syczewska M.  Ribavirin--pharmacological features, antiviral effects against hepatitis C virus (HCV) and other viruses and side effects during treatment[J]. <i>Przegl Epidemiol (in Polish)<\/i>, 2002, 56 Suppl 5: 35\u201340."},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.29","unstructured":"Bacon BR.  Managing hepatitis C[J]. <i>Am J Manag Care<\/i>, 2004, 10(2S): S30\u2013S40."},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.30","doi-asserted-by":"publisher","unstructured":"Verna EC, Morelli G, Terrault NA, et al.  DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort[J]. <i>J Hepatol<\/i>, 2020, 73(3): 540\u2013548.","DOI":"10.1016\/j.jhep.2020.03.031"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.31","doi-asserted-by":"publisher","unstructured":"Jing J, Liu C, Zhu S, et al.  Pathological and ultrastructural observations and liver function analysis of <i>Eimeria stiedai<\/i>-infected rabbits[J]. <i>Vet Parasitol<\/i>, 2016, 223: 165\u2013172.","DOI":"10.1016\/j.vetpar.2016.04.020"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.32","doi-asserted-by":"publisher","unstructured":"Chalouni M, Wittkop L, Bani-Sadr F, et al.  Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants[J]. <i>HIV Med<\/i>, 2021, 22(9): 791\u2013804.","DOI":"10.1111\/hiv.13127"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.33","doi-asserted-by":"publisher","unstructured":"Everhart JE, Wright EC.  Association of \u03b3-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV)[J]. <i>Hepatol Baltim Md<\/i>, 2013, 57(5): 1725\u20131733.","DOI":"10.1002\/hep.26203"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.34","doi-asserted-by":"publisher","unstructured":"Toyoda H, Tada T, Yasuda S, et al.  Dynamic evaluation of liver fibrosis to assess the risk of hepatocellular carcinoma in patients with chronic Hepatitis C who achieved sustained virologic response[J]. <i>Clin Infect Dis<\/i>, 2020, 70(6): 1208\u20131214.","DOI":"10.1093\/cid\/ciz359"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.35","doi-asserted-by":"publisher","unstructured":"Strazzulla A, Iemmolo RMR, Carbone E, et al.  The risk of hepatocellular carcinoma after directly acting antivirals for hepatitis C virus treatment in liver transplanted patients: is it real?[J]. <i>Hepat Mon<\/i>, 2016, 16(11): e41933.","DOI":"10.5812\/hepatmon.41933"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.36","doi-asserted-by":"publisher","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al.  AASLD guidelines for the treatment of hepatocellular carcinoma[J]. <i>Hepatology<\/i>, 2018, 67(1): 358\u2013380.","DOI":"10.1002\/hep.29086"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.37","doi-asserted-by":"publisher","unstructured":"European Association for Study of Liver, European Organisation for Research and Treatment of Cancer.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. <i>Eur J Cancer<\/i>, 2012, 48(5): 599\u2013641.","DOI":"10.1016\/j.ejca.2011.12.021"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.38","doi-asserted-by":"publisher","unstructured":"Santi V, Trevisani F, Gramenzi A, et al.  Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival[J]. <i>J Hepatol<\/i>, 2010, 53(2): 291\u2013297.","DOI":"10.1016\/j.jhep.2010.03.010"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.39","doi-asserted-by":"publisher","unstructured":"Strazzulla A, Coppolino G, Barreca GS, et al.  Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals[J]. <i>Clin Mol Hepatol<\/i>, 2018, 24(2): 151\u2013162.","DOI":"10.3350\/cmh.2017.0059"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.40","doi-asserted-by":"publisher","unstructured":"Mazzitelli M, Torti C, Sabatino J, et al.  Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients[J]. <i>BMC Infect Dis<\/i>, 2018, 18(1): 518.","DOI":"10.1186\/s12879-018-3426-9"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.41","doi-asserted-by":"publisher","unstructured":"Leu\u015ftean A, Popescu C, Nichita L, et al.  Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy[J]. <i>Exp Ther Med<\/i>, 2021, 21(1): 99.","DOI":"10.3892\/etm.2020.9531"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.42","doi-asserted-by":"publisher","unstructured":"Montasser MF, Zaky S, Salaheldin M, et al.  Fib-4 predicts early hematological adverse events induced by interferon-based triple therapy in chronic hepatitis C virus patients[J]. <i>J Interferon Cytokine Res<\/i>, 2019, 39(2): 85\u201394.","DOI":"10.1089\/jir.2018.0131"},{"key":"10.7555\/JBR.37.20230284.swyxyjzzywb.43","doi-asserted-by":"publisher","unstructured":"Yara\u015f S, Sezgin O, \u00dc\u00e7bilek E, et al.  Significant decrease in liver stiffness detected by two dimensional shear-wave elastography after treatment with direct-acting antiviral agents in patients with chronic hepatitis C[J]. <i>Turk J Gastroenterol<\/i>, 2020, 31(2): 142\u2013147.","DOI":"10.5152\/tjg.2020.19418"}],"container-title":["The Journal of Biomedical Research"],"original-title":[],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:08:52Z","timestamp":1727687332000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.37.20230284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"alternative-id":["JBR-2023-0284"],"URL":"https:\/\/doi.org\/10.7555\/jbr.37.20230284","relation":{},"ISSN":["1674-8301","1674-8301"],"issn-type":[{"type":"print","value":"1674-8301"},{"type":"electronic","value":"1674-8301"}],"subject":[],"published":{"date-parts":[[2024]]}}}